Advertisement
Document › Details
Gilead Sciences, Inc.. (1/30/20). "Press Release: Sandra Horning, MD, Joins Gilead Sciences’ Board of Directors". Foster City, CA.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Sandra Horning, MD, has been appointed to the company’s Board of Directors.
Dr. Horning retired in 2019 as Chief Medical Officer and Global Head of Product Development for Roche, after a 10-year career at Roche and Genentech during which she helped bring 15 new medicines to patients in disease areas including cancer, multiple sclerosis, influenza and blindness. Prior to her career at Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors and she currently serves as an advisor to EQRx.
“We are very pleased to welcome Sandra Horning to our Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “Sandra has significant industry expertise and vast experience in drug development across multiple therapeutic areas. In addition, she brings the perspective of a leading physician who has spent more than two decades caring for patients with cancer. Sandra’s presence on our Board will be a tremendous asset as we enter the next chapter for Gilead with the goal of rapidly advancing new, transformative medicines.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Douglas Maffei, Investors
(650) 522-2739
Amy Flood, Media
(650) 522-5643
Record changed: 2023-06-05 |
Advertisement
More documents for Gilead Sciences (Group)
- [1] Hookipa Pharma Inc.. (12/21/23). "Press Release: Hookipa Pharma Announces $21.25 Million Equity Investment from Gilead Sciences". New York, NY & Vienna....
- [2] Hookipa Pharma Inc.. (1/4/23). "Press Release: Hookipa Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine". New York, NY & Vienna....
- [3] BioNTech SE. (7/19/21). "Press Release: BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD". Mainz & Santo Monica, CA....
- [4] Gilead Sciences, Inc.. (12/10/20). "Press Release: Gilead Sciences to Acquire MYR GmbH". Foster City, CA & Bad Homburg....
- [5] MYR GmbH. (8/4/20). "Press Release: MYR Pharmaceuticals Receives Conditional Marketing Authorization by the European Commission for Hepcludex". Bad Homburg....
- [6] MYR GmbH. (6/10/20). "Press Release: MYR Pharmaceuticals Has Incorporated Its First European Subsidiary in France". Bad Homburg....
- [7] Gilead Sciences, Inc.. (7/19/19). "Press Release: Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis". Foster City, CA....
- [8] Gemoab GmbH. (7/16/19). "Press Release: Gemoab Announces the Appointment of Oncology Expert Michael Pehl as Chief Executive Officer". Dresden....
- [9] Hookipa Pharma Inc.. (5/8/19). "Press Release: Hookipa Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead". New York, NY & Vienna....
- [10] Gilead Sciences, Inc.. (4/12/19). "Press Release: Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH". Foster City & Bagsværd....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top